Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
SpyGlass Pharma, Inc. (SGP) had Cash Flow from Financial Activities of 124.58M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-39.87M |
|
-- |
|
-- |
|
41.45M |
|
-41.45M |
|
1.58M |
|
-39.87M |
|
-39.87M |
|
-39.87M |
|
-39.87M |
|
-39.87M |
|
-39.87M |
|
-41.45M |
|
-40.84M |
|
2.22M |
|
2.22M |
|
-17.98 |
|
-17.98 |
|
| Balance Sheet Financials | |
108.77M |
|
2.34M |
|
7.10M |
|
115.87M |
|
8.58M |
|
-- |
|
206.12M |
|
214.70M |
|
-98.84M |
|
-98.84M |
|
-98.84M |
|
2.20M |
|
| Cash Flow Statement Financials | |
-32.70M |
|
-11.79M |
|
|
Cash Flow from Financial Activities |
124.58M |
16.27M |
|
96.36M |
|
80.09M |
|
2.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.67 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-33.49M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
40.34% |
|
40.34% |
|
-34.41% |
|
40.34% |
|
-44.84 |
|
-15.11 |
|
-14.75 |
|